APA (7th ed.) Citation

Oneal, P. A., Kwitkowski, V., Luo, L., Shen, Y. L., Subramaniam, S., Shord, S., . . . Pazdur, R. (2018). FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim‐Chester Disease with the BRAFV600 Mutation. The oncologist (Dayton, Ohio), 23(12), 1520-1524. https://doi.org/10.1634/theoncologist.2018-0295

Chicago Style (17th ed.) Citation

Oneal, Patricia A., et al. "FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim‐Chester Disease with the BRAFV600 Mutation." The Oncologist (Dayton, Ohio) 23, no. 12 (2018): 1520-1524. https://doi.org/10.1634/theoncologist.2018-0295.

MLA (9th ed.) Citation

Oneal, Patricia A., et al. "FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim‐Chester Disease with the BRAFV600 Mutation." The Oncologist (Dayton, Ohio), vol. 23, no. 12, 2018, pp. 1520-1524, https://doi.org/10.1634/theoncologist.2018-0295.